Metagenomi Therapeutics (MGX) Shares Outstanding (2023 - 2026)

Metagenomi Therapeutics (MGX) has 4 years of Shares Outstanding data on file, last reported at $37.6 million in Q1 2026.

• Shares Outstanding for Q1 2026 came in at $37.6 million, up 0.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $37.6 million (up 0.71% YoY), and the FY2025 annual result was $37.6 million, up 0.54% from the prior year.
• Shares Outstanding steadied at $37.6 million in Q1 2026 per MGX's latest filing, from $37.6 million in the prior quarter.
• Over five years, Shares Outstanding peaked at $37.6 million in Q1 2026 and troughed at $3.4 million in Q1 2023.
• A 4-year average of $27.0 million and a median of $37.4 million in 2024 frame the typical range for Shares Outstanding.
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding surged 1000.52% in 2024, then declined 0.23% in 2025.
• A 4-year view of Shares Outstanding shows it stood at $3.4 million in 2023, then surged by 999.06% to $37.4 million in 2024, then climbed by 0.54% to $37.6 million in 2025, then gained by 0.07% to $37.6 million in 2026.
• Business Quant data shows MGX's Shares Outstanding at $37.6 million in Q1 2026, $37.6 million in Q4 2025, and $37.5 million in Q3 2025.